Protagonist Therapeutics, Inc.

Historical 13F Holders

Symbol
PTGX
CUSIP
74366E102
All holders as of
Q2 2026
Type
Equity
Class
COM
Reported Value, Excluding Options
Total Filings

13D/G Filers

Investors who own more than 5% of a class must file a Schedule 13D or 13G. Every filing for 74366E102 since 12/18/2024, newest first.

Filer % of Class Filed
Farallon Capital Management, L.L.C. 13G/A Amendment 9
10.0% 8/13/2026
Event 6/30/2026
State Street Corp 13G 5.2% 8/7/2026
Event 6/30/2026
State Street Corp 13G 4.9% 5/12/2026
Event 3/31/2026
Vanguard Capital Management LLC 13G 5.1% 4/30/2026
Event 3/31/2026
Vanguard Portfolio Management LLC 13G 5.5% 4/29/2026
Event 3/31/2026
Vanguard Group Inc 13G/A Amendment 5 0% 3/27/2026
Event 3/13/2026
RTW Investments, LP 13G/A Amendment 6
8.1% 2/17/2026
Event 12/31/2025
Wellington Management Group LLP 13G
5.1% 2/10/2026
Event 12/31/2025
Farallon Capital Partners, L.P. 13G/A Amendment 8
10.0% 2/6/2026
Event 12/31/2025
Vanguard Group Inc 13G/A Amendment 4 8.7% 1/30/2026
Event 12/31/2025
Deep Track Capital, LP 13G/A Amendment 1
2.8% 11/14/2025
Event 9/30/2025
Biotechnology Value Fund L P 13G/A Amendment 1
4.1% 11/14/2025
Event 9/30/2025
BlackRock, Inc. 13G/A Amendment 7 13.8% 10/17/2025
Event 9/30/2025
State Street Corp 13G 5.2% 8/11/2025
Event 6/30/2025
Biotechnology Value Fund L P 13G
5.2% 6/16/2025
Event 6/9/2025
State Street Corp 13G 4.4% 5/13/2025
Event 3/31/2025
BlackRock, Inc. 13G/A Amendment 6 14.8% 4/29/2025
Event 3/31/2025
Deep Track Capital, LP 13G
5.3% 4/10/2025
Event 4/3/2025
Farallon Capital Partners, L.P. 13G/A Amendment 7
10.0% 2/10/2025
Event 12/31/2024
BlackRock, Inc. 13G/A Amendment 5 16.6% 2/5/2025
Event 12/31/2024

13F Holders by Quarter

Period Filings Shares, Excl. Options Value, Excl. Options
2026 Q3 10 6.19 k $873 k
2026 Q2 361 83.0 M $9.35 B
2026 Q1 339 78.8 M $8.31 B
2025 Q4 338 71.0 M $6.18 B
2025 Q3 286 70.9 M $4.71 B
2025 Q2 290 71.5 M $3.95 B
2025 Q1 299 65.4 M $3.16 B
2024 Q4 255 63.8 M $2.46 B
2024 Q3 253 62.3 M $2.80 B
2024 Q2 200 59.8 M $2.07 B
2024 Q1 196 64.0 M $1.85 B
2023 Q4 165 59.6 M $1.37 B
2023 Q3 151 56.8 M $947 M
2023 Q2 188 56.7 M $1.57 B
2023 Q1 161 53.2 M $1.23 B
2022 Q4 147 52.8 M $576 M
2022 Q3 138 47.5 M $400 M
2022 Q2 147 53.4 M $422 M
2022 Q1 157 50.7 M $1.20 B
2021 Q4 175 49.9 M $1.70 B
2021 Q3 150 46.4 M $821 M
2021 Q2 143 48.2 M $2.16 B
2021 Q1 131 44.3 M $1.15 B
2020 Q4 135 44.1 M $889 M
2020 Q3 94 37.3 M $728 M
2020 Q2 88 34.3 M $605 M
2020 Q1 80 23.4 M $165 M
2019 Q4 84 23.5 M $165 M
2019 Q3 78 18.9 M $228 M
2019 Q2 67 17.2 M $208 M
2019 Q1 65 15.1 M $189 M
2018 Q4 68 14.0 M $94.0 M
2018 Q3 64 16.2 M $167 M
2018 Q2 70 14.2 M $95.6 M
2018 Q1 71 11.9 M $103 M
2017 Q4 66 11.8 M $246 M
2017 Q3 41 8.13 M $144 M
2017 Q2 44 8.12 M $91.8 M
2017 Q1 41 8.02 M $103 M
2016 Q4 39 8.00 M $175 M
2016 Q3 34 6.90 M $145 M